The TROPION-Breast01 phase III study evaluated Dato-DXd,a TROP2-directed ADC for treating inoperable or metastatic hormone ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

The Dato-DXd is based on the TROPION-Breast01, a phase 3 study comparing the physicians’ choice among patients with ER-positive, HER2-low or HER2-negative metastatic breast cancer who have had ...

Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Our peak revenue estimate is USD 11 billion. Dato-DXd is a clinical-stage TROP2 ADC that is being developed for lung cancer, triple negative breast cancer, and other cancer types. The company has ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven Phase III trials in lung cancer and five ...

Patients with breast cancer, colorectal cancer, melanoma and prostate cancer did not show an increased risk of any cardiovascular outcome. “The CVD risk in those taking aspirin was the same as that in ...